Skip to main
HURA

HURA Stock Forecast & Price Target

HURA Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

TuHURA Biosciences is estimated to have a value of $636M, indicating a 12-month price objective of $10 per share. Despite the risks of negative clinical results and delays, the company's promising pipeline and innovative technologies focused on tackling resistance in cancer immunotherapy make for a positive outlook. It also helps that the company operates in a single reportable segment, allowing for a more focused and efficient approach to advancing cancer therapies.

Bears say

TuHURA Biosciences is currently facing several key risks that could negatively impact their success, including the potential for negative clinical results for their flagship product IFx-2.0, delays in obtaining regulatory approvals, and competition from other checkpoint inhibitors. However, the recent decline in stock price creates an attractive entry point for investors due to upcoming value inflection points, including preliminary results from a Phase 1b/2a trial and interim/top-line results expected in 4Q26 and 1Q27, respectively. Therefore, the financial analyst's negative outlook on TuHURA Biosciences' stock is based on the inherent risks involved in the company's pipeline and the uncertain success of their products.

HURA has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TuHURA Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TuHURA Biosciences Inc (HURA) Forecast

Analysts have given HURA a Strong Buy based on their latest research and market trends.

According to 3 analysts, HURA has a Strong Buy consensus rating as of Jun 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TuHURA Biosciences Inc (HURA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.